In a previous study, our data showed that CUSP9v3 combined with Bcl-2/Bcl-xL inhibition using Navitoclax (ABT-263) resulted in predominantly synergistic antineoplastic activity among different glioblastoma models [32]. This evidence concerns the gene BCL2 and glioblastoma.